Survivin as a Multifaceted Oncogenic Driver and Therapeutic Target in Renal Cell Carcinoma. (PubMed, bioRxiv) - Sep 16, 2025 - "Collectively, these findings identify survivin as a multifaceted oncogenic driver in RCC that integrates cell cycle progression, cytoskeletal organization, and mitochondrial homeostasis. By revealing survivin's dual roles in proliferative and metabolic adaptation, this work highlights survivin as both a prognostic biomarker and a therapeutic vulnerability, supporting future strategies that combine survivin inhibition with metabolic or cell cycle-directed therapies for advanced kidney cancer."
Journal • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • BIRC5 • CCND1
|
|
Dave Gau; Gabrielle Inserra; Shivani Tuli; Yamato Murakami; Yongho Bae
|